Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The FDA is inviting public comments until June 29, 2026, before making a final determination.
Most weight loss occurs in the first 6 months of consistent use, after which the rate of loss typically stabilizes
Mazdutide and its comparison with retatrutide adds another dimension to the evolving landscape of metabolic peptide therapy
Lonborg, J
As interest in diabetes and weight-loss medications such as Ozempic, Wegovy, and Zepbound surged in recent years, supplement manufacturers responded by launching a number of GLP-1-branded products including pills, powders, drops, and patches
Lisco and colleagues published a review of the risks of GLP-1s and thyroid cancer in the journal Endocrine Connections in 2023, and although they describe evidence for a risk of thyroid cancer, they conclude: It is reasonable to continue prescribing GLP-1RAs due to the evidence of more relevant and well-recognized antihyperglycemic, cardiovascular, and renal benefits, with the management staying within current recommendations. If you are considering taking a GLP-1 but are concerned about the risk of thyroid cancer, you should discuss it with your doctor
